Four novel ULBP splice variants are ligands for human NKG2D

International Immunology

Volumn 20, Issue 8, 2008, Pages 981-991

  Cao, Wei ^a,b   Xi, Xueyan ^a,b   Wang, Zhun ^a,b   Dong, Liling ^c   Hao, Zhiyong ^a,b   Cui, Lianxian ^a,b   Ma, Chi ^a,b   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

MHC I like molecules; NK cells; Splice variants; Tumor immunity

Indexed keywords

BINDING PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; RETINOIC ACID EARLY TRANSCRIPT 1 G3; UL16 BINDING PROTEIN; UL16 BINDING PROTEIN 4;

AMINO ACID SEQUENCE; AMNION CELL; ANIMAL CELL; ARTICLE; CELL STIMULATION; CELL STRAIN HEPG2; CELL STRAIN K 562; CELL SURFACE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; GENETIC VARIABILITY; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SEQUENCE ALIGNMENT; TARGET CELL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; TRANSFECTION;

EID: 48249109843     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn057     Document Type: Article

References (49)

1. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3:781.
2. Cao, W. and He, W. 2004. UL16 binding proteins. Immunobiology 209:283.
3. Radosavljevic, M., Cuillerier, B., Wilson, M. J. et al. 2002. A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 79:114.
4. Radaev, S., Rostro, B., Brooks, A. G., Colonna, M. and Sun, P. D. 2001. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 15:1039.
5. Bacon, L., Eagle, R. A., Meyer, M., Easom, N., Young, N. T. and Trowsdale, J. 2004. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J. Immunol. 173:1078.
6. Carayannopoulos, L. N., Naidenko, O. V., Fremont, D. H. and Yokoyama, W. M. 2002. Cutting edge: Murine UL16-bindinA protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J. Immunol. 169:4079.
7. Sutherland, C. L., Chalupny, N. J., Schooley, K., VandenBos, T., Kubin, M. and Cosman, D. 2002. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J. Immunol. 168:671.
8. Cosman, D., Mullberg, J., Sutherland, C. L. et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123.
9. Jan Chalupny, N., Sutherland, C. L., Lawrence, W. A., Rein-Weston, A. and Cosman, D. 2003. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305:129.
10. Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R. and Spies, T. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255.
11. Das, H., Groh, V., Kuijl, C. et al. 2001. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83.
12. Diefenbach, A., Tomasello, E., Lucas, M. et al. 2002. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3:1142.
13. Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M. and Colonna, M. 2002. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3:1150.
14. Maasho, K., Opoku-Anane, J., Marusina, A. I., Coligan, J. E. and Borrego, F. 2005. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J. Immunol. 174:4480.
15. Markiewicz, M. A., Carayannopoulos, L. N., Naidenko, O. V. et al. 2005. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J. Immunol. 175:2825.
16. Rincon-Orozco, B., Kunzmann, V., Wrobel, P., Kabelitz, D., Steinle, A. and Herrmann, T. 2005. Activation of V gamma 9V delta 2 T cells by NKG2D. J. Immunol. 175:2144.
17. Meresse, B., Chen, Z., Ciszewski, C. et al. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21:357.
18. Dhanji, S., Teh, S. J., Oble, D., Priatel, J. J. and Teh, H. S. 2004. Self-reactive memory-phenotype CD8 T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: A role for the T-cell receptor and natural killer cell receptors. Blood 104:2116.
19. Verneris, M. R., Karami, M., Baker, J., Jayaswal, A. and Negrin, R. S. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103:3065.
20. Maccalli, C., Pende, D., Castelli, C., Mingari, M. C., Robbins, P. F. and Parmiani, G. 2003. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur. J. Immunol. 33:2033.
21. Nitahara, A., Shimura, H., Ito, A., Tomiyama, K., Ito, M. and Kawai, K. 2006. NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells. J. Invest. Dermatol. 126:1052.
22. Sutherland, C. L., Rabinovich, B., Chalupny, N. J., Brawand, P., Miller, R. and Cosman, D. 2006. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108:1313.
23. Diefenbach, A., Jensen, E. R., Jamieson, A. M. and Raulet, D. H. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165.
24. Zhou, H., Luo, Y., Lo, J. F. et al. 2005. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc. Natl Acad. Sci. USA 102:10846.
25. Zhou, H., Luo, Y., Kaplan, C. D. et al. 2006. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Blood 107:3251.
26. Groh, V., Wu, J., Yee, C. and Spies, T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734.
27. Salih, H. R., Rammensee, H. G. and Steinle, A. 2002. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol 169:4098.
28. Salih, H. R., Antropius, H., Gieseke, F. et al. 2003. Functional expression and release of ligands for the activating immuno-receptor NKG2D in leukemia. Blood 102:1389.
29. Waldhauer, I. and Steinle, A. 2006. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 66:2520.
30. Song, H., Kim, J., Cosman, D. and Choi, I. 2006. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 239:22.
31. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A. and Salih, H. R. 2006. Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol. Immunother 55:1584.
32. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A. and Salih, H. R. 2006. Soluble MICA in malignant diseases. Int. J. Cancer 118:684.
33. Marten, A., von Lilienfeld-Toal, M., Buchler, M. W. and Schmidt, J. 2006. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int. J. Cancer 119:2359.
34. Yokoyama, W. M. 2002. Immunology: Catch us if you can. Nature 419:679.
35. Cao, W., Xi, X., Hao, Z. et al. 2007. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J. Biol. Chem. 282:18922.
36. von Strandmann, E. P., Hansen, H. P., Reiners, K. S. et al. 2006. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107:1955.
37. Conejo-Garcia, J. R., Benencia, F., Courreges, M. C. et al. 2003. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol. Ther. 2:446.
38. Eagle, R. A., Traherne, J. A., Ashiru, O., Wills, M. R. and Trowsdale, J. 2006. Regulation of NKG2D ligand gene expression. Hum. Immunol. 67:159.
39. Pende, D., Rivera, P., Marcenaro, S. et al. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62:6178.
40. Li, P., Morris, D. L., Willcox, B. E., Steinle, A., Spies, T. and Strong, R. K. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol. 2:443.
41. Sanchez, R. and Sali, A. 2000. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol. Biol. 143:97.
42. Chen, R., Li, L. and Weng, Z. 2003. ZDOCK: An initial-stage protein-docking algorithm. Proteins 52:80.
43. Guex, N. and Peitsch, M. C. 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714.
44. Bahram, S., Inoko, H., Shiina, T. and Radosavljevic, M. 2005. MIC and other NKG2D ligands: From none to too many. Curr. Opin. Immunol. 17:505.
45. Eagle, R. A. and Trowsdale, J. 2007. Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7:737.
46. Dunn, C., Chalupny, N. J., Sutherland, C. L. et al. 2003. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J. Exp. Med. 197:1427.
47. Chalupny, N. J., Rein-Weston, A., Dosch, S. and Cosman, D. 2006. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun. 346:175.
48. Cerboni, C., Neri, F., Casartelli, N. et al. 2007. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J. Gen. Virol. 88:242.
49. Marten, A., von Lilienfeld-Toal, M., Buchler, M. W. and Schmidt, J. 2006. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int. J. Cancer 119:2359.